Great Place To Work
Summit Therapeutics is proud to have achieved the Great Place to Work® Certification™! Great Place to Work® is a globally recognized and trusted symbol of excellence and indicates Summit is committed to consistently providing our employees with a positive, supportive, and fulfilling work environment. Being recognized as a Great Place To Work® is a significant honor and speaks volumes about our company culture. It shows that we are committed to fostering a workplace where everyone can grow, succeed, and feel appreciated. Our employees are truly the heart and soul of our culture and are invaluable to shaping our future. We thank them for their extraordinary efforts and commitment.
Summit in the News
Congratulations Bob Duggan and Dr. Maky Zanganeh, our co-CEOs, on their recent CNBC interview.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA)
Committed to Optimizing Human Health
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health. Summit’s leadership is committed to making a significant positive difference in the quality and potential duration of life for oncology patients facing difficult diagnoses. Summit has enacted the path to providing patient, physician, caregiver, and societal-friendly therapies while creating opportunities for durable growth as a company by initiating two Phase III trials with its lead candidate, ivonescimab. Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central America, South America, and the Caribbean, the Middle East, and Africa, and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.
Ivonescimab displays cooperative binding with each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF. Ivonescimab was discovered by Akeso, Inc. (HKEX Code: 9926.HK). Ivonescimab is currently engaged in two Phase III clinical trials in Summit’s license territories, in addition to multiple Phase III clinical trials focused in China led by Akeso. Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC). Ivonescimab is an investigational therapy that is not approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).
Summit intends to expand the opportunity and potential of ivonescimab into additional solid tumors in the future, based on promising data being generated by our partners at Akeso in China, as well as potential investigator sponsored trials. Globally over 1,800+ have been treated with ivonescimab across all clinical trials to date, commencing in 2023 in Summit’s two Phase III clinical trials. Summit will continue to invest in our business and pipeline, driven by Team Summit’s unmatched capabilities, including our speed and operational excellence with the goal of bringing our mission into a reality.
A Message from Our Co-CEOs
Bob Duggan
Co-CEO & Chairman
“I am very proud of the efforts and accomplishments of Team Summit since we have entered into our very fruitful partnership with Akeso. Since our deal closed to in-license ivonescimab, our novel investigational bispecific antibody, we have initiated two Phase III clinical trials – HARMONi and HARMONi-3 – focused on patients suffering from different types of non-small cell lung cancer. We have accomplished this based on the conviction in our belief in ivonescimab. With our proven track record of success in the global development and commercialization of breakthrough oncology therapies, we believe the potential exists for enormous creation through this partnership – especially for patients facing high unmet medical needs who can benefit from innovative therapies.”
Dr. Maky Zanganeh
Co-CEO & President
“Our goal as an organization is to improve the quality of life and potential duration of life for patients experiencing significant challenges from a cancer diagnosis. We believe that ivonescimab has the opportunity to improve patient outcomes, starting with individuals facing non-small cell lung cancer, via its unique, intentionally-designed mechanism of action. Targeting both PD-1 and VEGF, ivonescimab is a novel bispecific antibody that was engineered to be greater than the sum of its parts. Through cooperative binding, ivonescimab was designed to improve upon previously established efficacy standards, in addition to side effects and safety profiles associated with these two targets, which we are investigating in our two Phase III trials. We are very excited to continue to develop ivonescimab in 2024 and beyond to help deliver on its potential to help as many patients as possible facing long-odds from a late-stage cancer diagnosis.”
